H.C. Wainwright reiterated a ‘Buy’ rating on MannKind with an $11 price target after the company’s update. ・The firm said it ...

This biotech innovator in inhaled therapeutics reported a notable insider sale amid ongoing product development and licensing activity.

Stock pickers are generally looking for stocks that will outperform the broader market. And the truth is, you can ...

MannKind Corporation (MNKD) saw a rise in its stock price after its third-quarter financial results exceeded market expectations. The company reported a quarterly revenue increase of 17.2%, reaching ...

・Afrezza revenue rose 23% to $18.49 million in the three months through the end of September, owing to higher prices and demand. ・Revenue from the V-Go insulin delivery patch, however, slipped 19% to ...

As of November 17, 2025, the average one-year price target for MannKind is $9.24/share. The forecasts range from a low of $7.07 to a high of $11.55. The average price target represents an increase of ...